Updates to Front-line Therapy in Hodgkin Lymphoma
Patients with advanced Hodgkin lymphoma (HL) have limited options. Although a high percentage of patients with HL are likely to be cured after front-line treatment, many patients experience short and long-term treatment-related toxicities, and a significant portion of patients are not fully responsive to therapy. Recent studies are demonstrating the utility of novel agents, including CD30 and PD-1-inhibitors, and modifications to existing regimens as viable front-line options in early-stage and advanced-stage HL. These novel options have the potential to significantly impact clinical practice and enhance patient outcomes. Oncology clinicians need to be aware of the data from clinical studies evaluating the utility of these treatment modalities to help them determine how to incorporate these novel agents into the standard of care for patients in order to improve patient outcomes.
This information was originally presented at the NCCN 13th Annual Congress: Hematologic Malignancies™ held in New York, New York, from September 21-22, 2018.
Target Audience
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this activity, participants should be able to:
- Summarize current front-line treatment options for Hodgkin lymphoma.
- Identify short- and long-term toxicities related to front-line treatment of Hodgkin lymphoma.
- Outline novel and emerging agents or modalities that may be incorporated as front-line therapy options for Hodgkin lymphoma.
Ranjana H. Advani, MD
Stanford Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Ranjana H. Advani, MD
Agensys, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fees, Honoraria
Bayer HealthCare: Consulting Fees, Honoraria
Bristol-Myers Squibb Company: Grant/Research Support
Celgene Corporation: Grant/Research Support
Forty Seven, Inc.: Grant/Research Support
Genentech, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fees, Honoraria
Infinity Pharmaceuticals, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Kite Pharma: Consulting Fee
Kura Oncology, Inc.: Grant/Research Support
Kyowa Hakko Kirin Co., Ltd.: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support
Seattle Genetics, Inc: Consulting Fees, Honoraria; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until 8/10/2018); Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer L. Burns, BS; Ndiya Ogba, PhD
Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.50 hour of Category 1 credit for completing this activity.
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.50 contact hour.
Pharmacists
National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.05 CEUs) of continuing education credit. UAN: 0836-0000-18-120-H01-P
Available Credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing